Gene Editing Stocks

Track and analyze companies pioneering CRISPR and advanced genetic engineering technologies

# Company Price Market Cap Gene Tech Angle Tags
1
Vertex Pharmaceuticals Incorporated
VRTX
$475.58 $122.48B CRISPR-based type 1 diabetes treatment CRISPR Diabetes Partnership
2
Alnylam Pharmaceuticals, Inc.
ALNY
$273.815 $35.32B RNAi therapeutic platform RNAi Platform Rare Disease
3
Moderna, Inc.
MRNA
$33.28 $12.81B mRNA therapeutic platform mRNA Platform Vaccines
4
Sarepta Therapeutics, Inc.
SRPT
$110.79 $10.58B Gene therapy for muscular disorders AAV DMD Muscle
5
Signify Health, Inc.
SGFY
$30.49 $8.93B Gene therapy manufacturing platform Manufacturing Platform Services
6
CRISPR Therapeutics AG
CRSP
$40.52 $3.46B Pioneer in CRISPR-Cas9 gene editing CRISPR Ex-Vivo Sickle Cell
7
Beam Therapeutics Inc.
BEAM
$27.45 $2.27B Base editing technology platform Base Editing Precision Platform
8
Rocket Pharmaceuticals, Inc.
RCKT
$10.4704 $1.11B Lentiviral gene therapy platform Lentiviral Rare Disease Platform
9
Intellia Therapeutics, Inc.
NTLA
$10.01 $1.02B In vivo CRISPR therapeutic applications CRISPR In-Vivo Liver
10
Ginkgo Bioworks Holdings, Inc.
DNA
$13.87 $797.78M Synthetic biology and gene writing Synthetic Bio Platform Writing
11
Sana Biotechnology, Inc.
SANA
$3.1385 $700.73M In vivo cell and gene therapy Cell Therapy Platform Research
12
Verve Therapeutics, Inc.
VERV
$8.26 $699.32M Base editing for cardiovascular disease Base Editing Cardiovascular Lipids
13
MeiraGTx Holdings plc
MGTX
$6.7501 $527.54M Gene therapy for ocular diseases AAV Ocular Manufacturing
14
Precigen, Inc.
PGEN
$1.64 $480.31M UltraCAR-T and gene therapy platform CAR-T Platform Oncology
15
REGENXBIO Inc.
RGNX
$8.425 $417.42M AAV-based gene therapy platform AAV Platform Rare Disease
16
Prime Medicine, Inc.
PRME
$2.54 $333.15M Prime editing technology platform Prime Editing Platform Research
17
ContextLogic Inc.
LOGC
$7.84 $206.08M Gene editing for CAR-T therapy CAR-T Platform Oncology
18
Solid Biosciences Inc.
SLDB
$3.0791 $123.02M Gene therapy for rare diseases AAV Rare Disease Muscle
19
Talaris Therapeutics, Inc.
TALS
$2.72 $116.44M Base editing for genetic diseases Base Editing Platform Research
20
Editas Medicine, Inc.
EDIT
$1.27 $104.84M CRISPR ocular and oncology programs CRISPR Ocular Oncology
21
bluebird bio, Inc.
BLUE
$6.4635 $62.84M Lentiviral gene therapy platform Lentiviral Blood Rare Disease
22
Precision BioSciences, Inc.
DTIL
$4.98 $39.30M ARCUS gene editing platform ARCUS Platform Research
23
Homology Medicines, Inc.
FIXX
$0.9347 $3.02M AAV gene therapy technology AAV CNS Platform
24
Applied Genetic Technologies Corporation
AGTC
$0.3936 $- AAV gene therapy for eye diseases AAV Ocular Rare Disease

CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?

On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.

News image

VRTX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Vertex Pharmaceuticals Incorporated

NEW YORK, NY / ACCESS Newswire / February 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

News image

ATTENTION Intellia Therapeutics, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights

NEW YORK, NY / ACCESS Newswire / February 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic priorities and key anticipated 2025 milestones".

News image

Mercado Libre CEO and Founder Marcos Galperin Reflects on the company's 25-Year Journey and DNA in Latest Episode of Inside Mercado Libre

Montevideo, Uruguay, 6 February 2025, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mercado Libre (NASDAQ: MELI), the leading e-commerce and fintech platform in Latin America, drops the fifth episode of its podcast series, Inside Mercado Libre, "Marcos Galperin on MELI's Culture” featuring its CEO and founder Marcos Galperin. The Inside Mercado Libre podcast, hosted by Investor Relations Officer, Richard Cathcart, provides investors with unique access to the company executives' strategic views.

News image

Strength Seen in Ginkgo Bioworks (DNA): Can Its 14.5% Jump Turn into More Strength?

Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

News image

Ginkgo Bioworks to Host 6th Annual Ferment as Boston-based Conference Series

Evolution of Ferment conference to kick off Summer 2025 BOSTON , Feb. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the 2025 Ferment Series, an evolution of its flagship annual conference dedicated to advancing Ginkgo's mission of making biology easier to engineer. Throughout 2025, Ginkgo product teams will hold a series of focused Ferments at Ginkgo's beautiful event venue, located at 19 Fid Kennedy Ave in Boston's historic Seaport District, just a five-minute walk from Ginkgo's headquarters.

News image

ATTENTION VRTX SHAREHOLDERS: Investors who Lost Money on Vertex Pharmaceuticals Incorporated are Urged to Contact Levi & Korsinsky About an Ongoing Investigation

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

News image

Did Intellia Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- NTLA

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic priorities and key anticipated 2025 milestones".

News image

CRISPR Therapeutics AG (CRSP) Guggenheim SMID Cap Biotech Conference (Transcript)

CRISPR Therapeutics AG (NASDAQ:CRSP ) Guggenheim SMID Cap Biotech Conference Transcript February 6, 2025 2:00 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay And thank you for joining Guggenheim during our second SMID Cap conference. I am Debjit, one of the therapeutic analysts here, and joining me from CRISPR Therapeutics is CEO, Samarth Kulkarni.

News image

Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)

Crispr Therapeutics AG's partnership with Vertex Pharmaceuticals offers financial support, mentorship, and validation, enhancing Crispr's approach and technology. Despite slower-than-expected Casgevy enrollment, Crispr's strong cash position and diversified drug pipeline bolster its long-term growth potential. Clinical progress includes expanding authorized treatment centers for Casgevy and advancing multiple drug candidates in hemoglobinopathies, CAR-T, and in vivo programs.

News image

Final Trades: Energy Transfer, Vertex Pharma, UnitedHealth and Axon Enterprise

The Investment Committee give you their top stocks to watch for the second half.

News image

Is VRTX a Portfolio Must Have After Two FDA Nods Ahead of Q4 Earnings?

On Vertex's Q4 earnings call, investors will focus on management's comments about launch preparation for Alyftrek (vanza triple) and Journavx (suzetrigine).

News image

Unlocking Q4 Potential of Vertex (VRTX): Exploring Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.

News image

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today provided an update on its existing patent portfolio.

News image

An Investigation Has Commenced on Behalf of Vertex Pharmaceuticals Incorporated Shareholders. Contact Levi & Korsinsky to Discuss your VRTX Losses.

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

News image

Intellia Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- NTLA

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic priorities and key anticipated 2025 milestones".

News image

Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $40.49, marking a +1.23% move from the previous day.

News image

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on February 1, 2025, it awarded an inducement grant to three new employees under Intellia's 2024 Inducement Plan as a material inducement to employment.

News image

VRTX STOCK ALERT: Levi & Korsinsky Notifies Vertex Pharmaceuticals Incorporated Investors of an Ongoing Investigation

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

News image

Lost Money on Intellia Therapeutics, Inc.(NTLA)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic priorities and key anticipated 2025 milestones".

News image

Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?

Vertex Pharmaceuticals (VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in earnings. But Vertex now is showing that it also can be a game changer when it comes to treating one of the most common of health problems -- pain.

News image

Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $470.37, marking a +1.88% move from the previous day.

News image

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on January 31, 2025, the company granted equity awards to eight new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

News image

Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains?

Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

News image

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

News image

3 Magnificent Stocks to Buy and Hold Forever

Some people are fair-weather friends; others are lifelong. It's a similar story with stocks.

News image

Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?

Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.

News image

Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?

Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.

News image

Lost Money on Vertex Pharmaceuticals Incorporated(VRTX)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky

NEW YORK, NY / ACCESS Newswire / February 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

News image

NTLA ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Intellia Therapeutics, Inc. investment

NEW YORK, NY / ACCESS Newswire / February 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic priorities and key anticipated 2025 milestones".

News image

Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?

Vertex Pharmaceuticals (VRTX 5.31%) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic fibrosis (CF).

News image

Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (VRTX 5.31%) are down about 9% from a peak the stock set in November, despite some highly positive news.

News image

Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges: variable efficacy vs opioids, generic competition, and entrenched prescriber habits limit near-term potential. Phase 2 LSR trial showed minimal benefit vs placebo, raising concerns about $11B peak sales estimates and success in ongoing diabetic neuropathy trial (completion in 2027). Conservative market expectations: Acute pain market $10-20B; $1.5B sales (10% share) more realistic. Must compete with established generics in neuropathic pain market.

News image

Intellia Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- NTLA

NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic priorities and key anticipated 2025 milestones".

News image

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Intellia Therapeutics, Inc - NTLA

NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ:NTLA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

News image

Vertex: YOY Decline In Q4 Earnings Expected, But Revenue Continues To Shine

Expectation is a decline in Vertex's earnings, but double-digit revenue growth should continue with the newly approved non-opioid drug JOURNAVX and CF franchise expansion. JOURNAVX, the first non-opioid oral pain signal inhibitor approved in over 20 years, targets a large market, potentially boosting Vertex's revenue significantly over time. The company's CF franchise continues to expand with new approvals and treatments, including TRIKAFTA, ALYFTREK, and VX-522, targeting a broader patient base.

News image

Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug

JOURNAVX, a non-opioid analgesic, shows significant promise in treating pain with a superior safety profile, addressing a critical unmet need compared to opioids with FDA approval just announced. Vertex Pharmaceuticals continues to execute its commercialization of three new drugs, JOURNAVX, CASGEVY, and ALYFTREK. Two of which have been approved by the FDA since December. Vertex's valuation appears high due to recent expenses, but analysts expect substantial earnings growth in 2025 as acquisition and clinical expenses subside.

News image

VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares Up

The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.

News image

FDA approves a new painkiller for the first time in decades

Vertex Pharmaceuticals' non-opioid painkiller comes without the potential risk of addiction. Transcript: Conway Gittens: Wall Street heads into the weekend with modest strength - and that's no small feat given how the week began.

News image

Biotech Stock Rises After FDA Approves Non-Opioid Painkiller

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug Administration (FDA) approved the biotech's new non-opioid painkiller, Journavx.

News image

Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm

NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Verve Therapeutics, Inc. (NASDAQ: VERV) breached their fiduciary duties to shareholders.  The investigation concerns potential self-dealing.

News image

Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval

Shares of Vertex Pharmaceuticals (VRTX) surged Friday, a day after the drugmaker reported federal regulators have approved its non-opioid painkiller, the first such drug to head to market in two decades.

News image

Vertex Pharmaceuticals CEO on non-opioid painkiller: It's safe, effective and non-addictive

CNBC's Angelica Peebles and Vertex JournavxPharmaceuticals CEO Reshma Kewalramani join 'Squawk on the Street' to discuss the FDA's approval of the company's non-opioid painkiller pill Journavx, a new alternative for pain relief that comes without the risk of addiction, concerns around drug effectiveness and costs, and more.

News image

What's Happening With VRTX Stock?

Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can potentially garner $4 billion in annual peak sales.

News image

Vertex Pharmaceuticals Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VRTX

NEW YORK, NY / ACCESS Newswire / January 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

News image

Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.

News image

FDA approves Vertex's non-opioid painkiller, first new kind of pain medicine in decades

CNBC's Becky Quick reports on the latest news.

News image

Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday's market open after the Food and Drug Administration approved the company's non-opioid pain treatment.

News image

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY's use in the NHS. It means that eligible SCD patients in England now have access to the therapy follo.

News image

FDA Approves Non-Opioid Painkiller With No Addiction Risk

The Food and Drug Administration approved Vertex Pharmaceuticals' “Journavx” on Thursday, greenlighting the non-opioid painkiller for treating moderate to severe pain in what the FDA considered the start of a new class of non-addictive medicines.

News image

Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller

Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.

News image

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. JOURNAVX is an effective, well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain. “Today's approval is a histori.

News image

Frequently Asked Questions

Gene editing technologies include:
  • CRISPR-Cas9 - Precision DNA editing
  • Base Editing - Single base modifications
  • Prime Editing - Advanced DNA rewriting
  • ZFN - Zinc finger nucleases
  • TALEN - Transcription activator-like effectors

The leading gene editing companies by market cap include:
  • VRTX - Vertex Pharmaceuticals Incorporated
  • ALNY - Alnylam Pharmaceuticals, Inc.
  • MRNA - Moderna, Inc.
  • SRPT - Sarepta Therapeutics, Inc.
  • SGFY - Signify Health, Inc.

Major applications include:
  • Genetic Diseases - Disease correction
  • Cancer Therapy - Cell engineering
  • Agriculture - Crop improvement
  • Rare Diseases - Genetic treatments
  • Research Tools - Scientific applications

Key investment considerations include:
  • Revolutionary technology
  • Broad therapeutic potential
  • Strong IP protection
  • Multiple applications
  • Partnership opportunities

Key factors affecting gene editing stocks include:
  • Clinical trial results
  • Patent developments
  • Technical advances
  • Regulatory decisions
  • Partnership deals
  • Safety profile